MedTrace Logo

TDCs to Treat Drug-resistant Epilepsy

NCT05825274 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-05-08

No results posted yet for this study

Summary

Epilepsy is the fourth overall neurologic disorder, regardless of age and gender. It encompass a wide spectrum of conditions, intensities and seizure types; therefor, several drugs have proven to treat different types of seizures. However, around 22.5 % of patients are unable to attain control regardless of the drug used or even a combination of several of them. TDCs offers a non-invasive approach with a focal effect for those patients. The focus of this study is to define the role for tDCS in the treatment of drug-resistant epilepsy on children.

Conditions

  • Other Forms of Epilepsy, Treatment Resistant

Interventions

DEVICE

Cathodal tDCS

We do 2 sessions per week of 35 minutes with cathodal electrodes over epileptic focus

Sponsors & Collaborators

  • Spanish Foundation for Neurometrics Development

    lead OTHER

Principal Investigators

  • Jean Neville, MD · New Remedies Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Months
Max Age
120 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2017-10-01
Completion
2017-12-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05825274 on ClinicalTrials.gov